Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2018 1
2019 3
2020 1
2021 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
Cejuela M, Gil-Torralvo A, Castilla MÁ, Domínguez-Cejudo MÁ, Falcón A, Benavent M, Molina-Pinelo S, Ruiz-Borrego M, Salvador Bofill J. Cejuela M, et al. Among authors: salvador bofill j. Int J Mol Sci. 2023 May 9;24(10):8488. doi: 10.3390/ijms24108488. Int J Mol Sci. 2023. PMID: 37239834 Free PMC article.
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Lluch A, et al. Among authors: bofill js. J Clin Oncol. 2020 Jan 20;38(3):203-213. doi: 10.1200/JCO.19.00904. Epub 2019 Dec 5. J Clin Oncol. 2020. PMID: 31804894 Free PMC article. Clinical Trial.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: bofill js. Breast Cancer Res Treat. 2021 Oct;189(3):689-699. doi: 10.1007/s10549-021-06334-0. Epub 2021 Aug 19. Breast Cancer Res Treat. 2021. PMID: 34414532 Free PMC article. Clinical Trial.
Evaluation of Nutritional Interventions in the Care Plan for Cancer Patients: The NOA Project.
García-Luna PP, Rabat Restrepo JM, Muñoz-Ayllón M, de la Calle Gil M, Remón P, Sánchez-Torralvo FJ, Pachón J, García-González JJ, García-Manrique T, Salvador-Bofill J, Vicente D, Olveira G. García-Luna PP, et al. Among authors: salvador bofill j. Nutrients. 2023 Jan 6;15(2):292. doi: 10.3390/nu15020292. Nutrients. 2023. PMID: 36678163 Free PMC article.
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Salvador Bofill J, Moreno Anton F, Rodriguez Sanchez CA, Galve Calvo E, Hernando Melia C, Ciruelos Gil EM, Vidal M, Jiménez-Rodriguez B, De la Cruz Merino L, Martínez Jañez N, Villanueva Vazquez R, de Toro Salas R, Anton Torres A, Alvarez Lopez IM, Gavila Gregori J, Quiroga Garcia V, Vicente Rubio E, De la Haba-Rodriguez J, Gonzalez-Santiago S, Diaz Fernandez N, Barnadas Molins A, Cantos Sanchez de Ibargüen B, Delgado Mingorance JI, Bellet Ezquerra M, de Casa S, Gimeno A, Martin M. Salvador Bofill J, et al. Breast. 2022 Dec;66:77-84. doi: 10.1016/j.breast.2022.09.006. Epub 2022 Sep 28. Breast. 2022. PMID: 36206609 Free PMC article. Clinical Trial.
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Cottu P, Ring A, Abdel-Razeq H, Marchetti P, Cardoso F, Salvador Bofill J, Martín M, Menon-Singh L, Wu J, De Laurentiis M. Cottu P, et al. Among authors: salvador bofill j. Breast. 2022 Apr;62:75-83. doi: 10.1016/j.breast.2022.01.016. Epub 2022 Jan 31. Breast. 2022. PMID: 35131646 Free PMC article. Clinical Trial.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: bofill js. Breast Cancer Res Treat. 2022 Jan;191(1):223-224. doi: 10.1007/s10549-021-06374-6. Breast Cancer Res Treat. 2022. PMID: 34625861 Free PMC article. No abstract available.
[Analysis of nutritional interventions in the care process of oncological patients in Andalusia - The NOA project].
García Luna PP, Calañas Continente A, Villarrubia Pozo A, Jiménez Lorente CP, Vicente Baz D, Castanedo OI, Salvador Bofill J, Rabat Restrepo JM, Díaz Gómez L, Mediano Rambla MD, Brozeta Benítez T, Muñoz Lucero T, Olveira G. García Luna PP, et al. Among authors: salvador bofill j. Nutr Hosp. 2021 Jul 29;38(4):758-764. doi: 10.20960/nh.03444. Nutr Hosp. 2021. PMID: 33703912 Free article. Spanish.
13 results